Please ensure Javascript is enabled for purposes of website accessibility

CDC: U.S. Coronavirus-Related Deaths to Start Falling Next Week

By Eric Volkman – Aug 21, 2020 at 9:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If realized, that trend would match the recent downward trajectory of total cases.

Thanks largely to a decline in one coronavirus hotspot, the number of deaths from COVID-19 -- the disease it can trigger -- should begin to fall next week. That, at least, was the prediction of Dr. Robert Redfield, director of the government's Centers for Disease Control and Prevention (CDC).

Following persistent urging from healthcare professionals, combined with mandates from many municipalities and states, much of the population seems to be complying with measures such as social distancing and habitual mask-wearing in public.

Four doctors with masks walking down hospital corridor.

Image source: Getty Images.

This is one reason Redfield is sounding an optimistic note on what's to come soon. "I think we're going to start to see a decline in mortality across the country now next week as we continue to get control of these cases," he said in an interview with Dr. Howard Bauchner of the influential Journal of the American Medical Association.

If his hope is realized, fatalities from the disease will start to follow the trajectory of total cases, which, on a national level, have been on the decline for nearly one month. On Thursday, for example, according to data compiled by The Wall Street Journal, the number of daily new cases was below 50,000 for the sixth day in a row, at a total of slightly over 44,000.

There's currently no widely approved drug to treat coronavirus/COVID-19, nor is there a vaccine.

Numerous biotech and pharmaceutical companies are developing such products. A few -- such as Moderna's mRNA-1273 vaccine candidate -- are in late-stage clinical trials.

One drug, the repurposed remdesivir from Gilead Sciences is being used to treat the disease. However, it has received only Food and Drug Administration Emergency Use Authorization, only for use in certain instances.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.32 (1.02%) $0.63
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$120.99 (2.32%) $2.74

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.